This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
There’s bias in both the training data sets and in the results, and there are ethical concerns, runaway costs, integration challenges, model drift, lack of transparency, data security risks, plagiarism risks, and regulatory risks. In addition, for particularly sensitive business information and data, he expects to see even more security.
Startups that survive the funding drought and succeed in securing allocations will be those with experienced, executive-level leadership and compelling customer-centric solutions. These prospects are more likely to secure financing ahead of their more risky, underdeveloped counterparts.
Clinical Pipelines and Drug Developments – Assessing the pipeline of pharmaceutical and biotechnology companies by analyzing clinical trials to gauge the potential success of new drugs or therapies in development.
These intangible factors indicate that even the most exhaustive duediligence processes can still leave gaps in the M&A research process. Comprehensive DueDiligence Thorough duediligence on a target company is undeniably the cornerstone of successful M&A.
ESG investing –it’s a market trend that’s gained traction with ethical investors, multi-billion dollar companies, mammoth private equity firms, and recently, the Securities and Exchange Commission (SEC) and International Sustainability Standards Board ( ISSB ). timber, natural pharmaceuticals) and services (i.e.,
Although, they’re trying to make TPU as a more open framework.” – Former Head of Engineering, Google | Expert Transcript When a pharmaceutical company launches a new drug, how do you know if the benefits to patients outweigh the side effects and costs? If you’re going to force me into TPU, that’s like locking me in.
Massive Data Analysis It’s clear that the pharmaceutical industry is increasingly in need of handling and interpreting expansive datasets efficiently and accurately. In the realm of supplier relations, AI applications provide transparency and foster collaboration between pharmaceutical companies and their partners.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content